OKUR (OnKure Therapeutics) Q4/FY2025 Earnings & Business Update

Price: ~$11.50 Market Cap: ~$160M Stage: Clinical (Phase 1a/1b) Focus: PI3Kalpha mutation-selective inhibitors, HR+/HER2+ breast cancer, vascular malformations

The Numbers

• Revenue: Zero. Pre-revenue clinical stage

• R&D Q4: $10.7M (down from $14.4M YoY)

• R&D FY2025: $48.3M (up from $43.8M)

• G&A FY2025: $14.7M (up from $10.6M)

• Net Loss FY2025: $59.5M (up from $52.7M)

• Cash: $59.1M at year-end. Burned ~$51.7M in 2025

• Post-earnings raise: $150M oversubscribed private placement announced March 27, led by Access Biotechnology. That changes the math completely. Cash position goes from ~$59M to ~$209M. Runway extends well past 2027

The $150M raise is the headline here, not the earnings. They went from roughly one year of runway to three-plus years overnight, and it was oversubscribed. That tells you the smart money likes the data they're seeing.

Pipeline

• OKI-219 (PI3Kalpha H1047R selective): Phase 1a/1b PIKture-01 trial. 71 patients dosed across monotherapy and fulvestrant combo arms. Triplet arm (OKI-219 + fulvestrant + ribociclib) has 17 patients dosed. HER2+ triplet arm (OKI-219 + trastuzumab + tucatinib) also enrolling. Updated data from Parts A, B, and Part E expected March 2026

• Next-gen PI3Kalpha pan-mutant inhibitor: Development candidate announcement expected March 2026. Targets broader PI3Kalpha mutation spectrum beyond just H1047R. The $150M raise specifically funds this program

• Vascular malformations: PI3Kalpha mutations are the most common driver in key subtypes. Details expected later 2026. Strategic expansion beyond oncology

Context

This is directly relevant to the Novartis/Synnovation deal. Novartis just paid $3B for a PI3Kalpha inhibitor (SNV4818) in HR+/HER2- breast cancer. OnKure is in the same exact vertical with a mutation-selective approach. OKUR's market cap is ~$160M. Novartis paid $3B. The comp is sitting right there.

The difference is OnKure's approach is mutation-selective rather than pan-PI3Kalpha, which theoretically gives a better safety profile. The historical problem with PI3K inhibitors (Alpelisib/Piqray) has always been toxicity. If OKI-219 can show comparable efficacy with a cleaner safety profile, the value gap between OKUR at $160M and the Novartis/Synnovation $3B deal closes fast.

Catalysts

• PIKture-01 updated data, Parts A/B and Part E (March 2026, imminent)

• Next-gen pan-mutant development candidate announcement (March 2026)

• Part C initial data, HER2+ triplet (2026)

• Vascular malformations program details (2026)

Tag: Dual Catalyst

M&A comp is already established. Novartis paid $3B for a PI3Kalpha program this month. The mutation-selective angle is differentiated. Cash is no longer a concern with the $150M raise. If the March data readout is clean, this name sits in the crosshairs of every pharma company building a PI3K franchise. Standalone growth trajectory is also viable with the expanded cash runway funding multiple programs into late-stage development.